Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma's subsidiary, ReceptoPharm, has received patent for its Multiple Sclerosis (MS) drug from the United States Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
The patent, ‘Modified anticholinergic neurotoxins as modulators of the autoimmune reaction’ describes a composition of matter and method of its use to treat multiple sclerosis in humans.
The composition is a modified anticholinergic alpha-neurotoxin.
Nutra Pharma CEO Rik J Deitsch said such patents are key to the continuing development of their pipeline and provide the value for eventual commercialization of the technology or out-licensing of the drugs.
"We currently own or license twelve patents that protect a broad range of drug and medical device technologies," Deitsch added.